ストックスクリーナーアプリを入手
1.625
0.31%
-0.005
前日終値:
$1.63
開ける：
$1.67
24時間の取引高:
259.81K
Relative Volume:
0.24
時価総額：
$214.55M
収益：
$79,600
当期純損益:
$-48.26M
株価収益率:
-3.3015
EPS:
-0.4922
ネットキャッシュフロー:
$-28.24M
1週間 パフォーマンス:
-4.97%
1か月 パフォーマンス:
-21.12%
6か月 パフォーマンス:
+12.85%
1年 パフォーマンス:
-17.09%
1日の値動き範囲:
$1.615
$1.68
1週間の範囲:
$1.61
$1.735
52週間の値動き範囲:
$1.33
$2.26
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
(302) 295-3800
住所
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.625 | 215.21M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
445.93 | 113.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
617.44 | 66.62B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
881.75 | 55.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.13 | 40.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.82 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2026-01-21 | 開始されました | BofA Securities | Buy |
| 2025-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
IKT Technical Analysis | Trend, Signals & Chart Patterns | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Therapeutics (IKT) Recovers 3.5% as Buyers Defend Key Support LevelMAMA Signal - The Legal Advocate
Inhibikase Therapeutics (IKT) Holds Near Support Amid Narrow Trading RangeScalping Stock Signals - The Legal Advocate
Inhibikase Therapeutics (IKT) Dips 2.87% as Stock Approaches Critical Support at $1.61RSI Oversold Picks - The Legal Advocate
Inhibikase Therapeutics (IKT) Faces Selling Pressure as Stock Retreats to $1.69Parabolic SAR - Newser
Inhibikase Therapeutics (IKT) Q1 2026 Earnings: Narrowing Losses as Pipeline Progress Takes Center StageShared Momentum Picks - Newser
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibikase Gains EU Clearance for Global PAH Trial - MyChesCo
Inhibikase Therapeutics, Inc. (IKT) Competitors - Meyka
IKT Stock Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 By Investing.com - Investing.com Nigeria
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Cantor Fitzgerald Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 - Investing.com India
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT) - The Globe and Mail
BofA Securities Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
ADAR1 reports 9.9% stake in Inhibikase (NASDAQ: IKT) via managed accounts - Stock Titan
Trails Edge holds 8.06M Inhibikase shares — Trails Edge (NASDAQ: IKT) - Stock Titan
Commodore Capital (IKT) reports 14.05M shares equivalent, 9.9% cap - Stock Titan
Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan
Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors - TipRanks
Is Inhibikase Therapeutics (IKT) Fairly Valued After Q1 2026 EPS - GuruFocus
Inhibikase Advances PAH Drug with Global Phase 3 Trial Launch - BriefGlance
Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum - ChartMill
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase (NASDAQ: IKT) deepens Q1 loss as pivotal PAH trial advances globally - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INHIBIKASE THERAPEUTICS ($IKT) Releases Q1 2026 Earnings - Quiver Quantitative
Inhibikase (NASDAQ: IKT) advances IMPROVE-PAH as Q1 2026 loss widens - Stock Titan
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension - TipRanks
Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat
What XXxs fundamentals reveal about its future (Rallies) 2026-05-08AI Powered Stock Picks - Newser
Inhibikase Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
How Inhibikase Therapeutics (IKT) is navigating logistics challenges | Q4 2025: EPS Tops ViewsPro Trader Recommendations - newser.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
IKT Inhibikase Therapeutics beats Q4 2025 loss estimates, shares post modest gains following earnings release.Quarterly Profit Report - newsline.com
[DEF 14A] Inhibikase Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
[ARS] Inhibikase Therapeutics, Inc. SEC Filing - Stock Titan
Inhibikase Therapeutics notches 13.6% EPS beat on narrower lossSpecial Dividend - newser.com
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inhibikase Therapeutics (IKT) asks shareholders to add 3M plan shares - Stock Titan
Inhibikase enrolls first patient in phase 3 PAH trial - MSN
Inhibikase Therapeutics (IKT) Stock Trading Today (+7.65%) 2026-04-18Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
1.10%
大文字化:
|
ボリューム (24 時間):